Sana Biotechnology/SANA

$7.76

0.39%
-
1D1W1MYTD1YMAX

About Sana Biotechnology

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.

Ticker

SANA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Steven Harr

Employees

328

Headquarters

Seattle, United States
Website
sana.com

SANA Metrics

BasicAdvanced
$1.81B
Market cap
-
P/E ratio
-$1.46
EPS
-
Beta
-
Dividend rate
$1.81B
$12.00
$2.75
2.04M
3.311
-40.81%
-72%
-46.74%
5.684
20.615
-2.5%

What the Analysts think about SANA

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
43.94% upside
High $15.00
Low $5.00
$7.76
Current price
$11.17
Average price target

SANA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-88.1M
-9,888.89%
Profit margin
0%
-

SANA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 7.89%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.43
-$0.59
$0.02
-$0.41
-
Expected
-$0.45
-$0.43
-$0.45
-$0.38
-$0.32
Surprise
-3.73%
38.28%
-104.48%
7.89%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Sana Biotechnology stock?

Sana Biotechnology (SANA) has a market cap of $1.81B as of April 19, 2024.

What is the P/E ratio for Sana Biotechnology stock?

The price to earnings (P/E) ratio for Sana Biotechnology (SANA) stock is 0 as of April 19, 2024.

Does Sana Biotechnology stock pay dividends?

No, Sana Biotechnology (SANA) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Sana Biotechnology dividend payment date?

Sana Biotechnology (SANA) stock does not pay dividends to its shareholders.

What is the beta indicator for Sana Biotechnology?

Sana Biotechnology (SANA) does not currently have a Beta indicator.

What is the Sana Biotechnology stock price target?

The target price for Sana Biotechnology (SANA) stock is $11.17, which is 43.94% above the current price of $7.76. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Sana Biotechnology stock

Buy or sell Sana Biotechnology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing